摘要
目的：探讨多西他赛联合顺铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效。方法：评价分析27例经病理学或细胞学确诊的晚期非小细胞肺癌患者予以多西他赛联合顺铂治疗,多西他赛75mg/m^2,第1天静脉滴注;顺铂75mg/m^2,第1天静脉滴注;28d为1个周期,观察治疗2-3个周期后的临床疗效及毒副作用。结果：27例中,总有效率为40.74%,中位生存时间38周,一年生存率40%;主要毒副反应为骨髓抑制,无治疗相关性死亡。结论：多西他赛联合顺铂是治疗晚期非小细胞肺癌的较好方案之一,毒副反应可以耐受,值得临床推广应用。
Objective：To investigate the effect of docetaxel combined with cisplatin in treating advanced non-small cell lung cancer（NSCLC）.Methods：27 cases confirmed by pathology or cytology in advanced NSCLC were treated by docetaxel combined cisplatin：the application of docetaxel was 75 mg/m2 on day 1 by intravenous infusion;The dose of cisplatin was 75mg/m2 by intravenous infusion on day 1.28 days was as a period.After 2~3 cycles the clinical efficacy and side effects was observed.Results：In 27 cases the total effective rate was 40.74%.The median survival time was 38 weeks and one year survival rate was 40%.The main adverse reaction was bone marrow suppression.There was no treatment-related death.Conclusion：Docetaxel combined cisplatin is one of the treatment parotocols in advanced NSCLC and it is worthy of clinical application.
出处
《医学理论与实践》
2011年第3期256-257,共2页
The Journal of Medical Theory and Practice
